Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
NCT04545554Phase 1Completed
- Sponsor
- Amgen
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of romosozumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Amgen. Primary endpoints: Maximum Observed Serum Concentration at Day 57, Time to Cmax at Day 57 and 3 more. Started Jan 2021; status: completed.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT04545554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545554.